<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129422">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01892176</url>
  </required_header>
  <id_info>
    <org_study_id>DSRB/2010/00223</org_study_id>
    <nct_id>NCT01892176</nct_id>
  </id_info>
  <brief_title>Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease</brief_title>
  <official_title>Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesise that measuring biomarkers of oxidative damage could better
      inform investigators on the potential merits (and pitfalls) of CoQ10 supplementation in PD
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with idiopathic PD will be recruited to a 10-week dose escalation study. Each
      dosage (400mg/day, 800mg/day, 1200/day and 2400mg/day) will be consumed daily for two weeks.
      Information on safety and fasting blood/urine samples will be collected. Primary endpoint is
      plasma F2-isoprostanes (adjusted for arachidonate) while secondary endpoint is the change in
      the total Unified Parkinson Disease Rating Scale (UPDRS) before and after treatment. Serum
      phospholipase A2 activities, plasma all trans-retinol, plasma total tocopherol (sum of α-,
      δ- and γ-tocopherol) and serum uric acid will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Biomarkers of oxidative damage</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg/day, 800mg/day, 1200/day and 2400mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme q10</intervention_name>
    <description>400mg/day, 800mg/day, 1200/day and 2400mg/day</description>
    <arm_group_label>Coenzyme Q10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic Parkinson disease

          -  age &gt;21 years

          -  able to provide written informed consent

        Exclusion Criteria:

          -  diabetes mellitus, stroke, cardiac and renal diseases and cigarette smoking

          -  major psychiatric disorder or drug and/or alcohol abuse/dependence

          -  regular use of antioxidants, dietary supplements, traditional Chinese remedies,
             non-steroidal anti-inflammatory drugs or immunosuppressive drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Seet, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Health System</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 8, 2013</lastchanged_date>
  <firstreceived_date>June 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University Hospital, Singapore</investigator_affiliation>
    <investigator_full_name>Medicine</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>coenzyme Q10, Parkinson disease, oxidative damage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
